Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis

BACKGROUND: A recently overall survival (OS) analysis from the AURA3 trial indicated that osimertinib improves median OS versus platinum-pemetrexed for patients with previously treated epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC). Here, we assessed the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yin, Pei, Rui, Liu, Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619214/
https://www.ncbi.nlm.nih.gov/pubmed/36324594
http://dx.doi.org/10.3389/fonc.2022.833773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619214/
https://www.ncbi.nlm.nih.gov/pubmed/36324594
http://dx.doi.org/10.3389/fonc.2022.833773

Ejemplares similares